Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03833934 · OUTCOME

Changed Treatment for NSCLC

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance · Source last updated 2025-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
32 months

What was measured

Initiated a new ALK tyrosine kinase inhibitor for treatment of NSCLC following enrollment in the study

Analysis population: Patients with at least 3 months of follow-up time

Groups in this outcome

ALK-positive NSCLC With Progression

Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ALK-positive NSCLC With Progression59

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ALK-positive NSCLC With Progression49Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        49
denoms
  1. counts
    1. group Id
      OG000
      value
      59
    units
    Participants
description
Initiated a new ALK tyrosine kinase inhibitor for treatment of NSCLC following enrollment in the study
groups
  1. description
    Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)
    id
    OG000
    title
    ALK-positive NSCLC With Progression
param Type
COUNT_OF_PARTICIPANTS
population Description
Patients with at least 3 months of follow-up time
reporting Status
POSTED
time Frame
32 months
title
Changed Treatment for NSCLC
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice